Bad Tracleer data do Actelion good
This article was originally published in Scrip
Executive Summary
Actelion's share price rose 2.41% to CHF89.15 after it unveiled negative trial results for the drug that provides the lion's share of its revenues. The Swiss firm's long-marketed Tracleer (bosentan) for the serious orphan disease pulmonary arterial hypertension has failed a Phase IV study measuring its ability to prolong the time before patients progress to first morbidity or mortality when they are already being treated with another drug, sildenafil.